ArticleCureus2025
Severe Cutaneous Adverse Reaction to Lamotrigine: A Case of Stevens-Johnson Syndrome in a Psychiatric Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stevens-Johnson syndrome (SJS) is a severe and potentially life-threatening mucocutaneous reaction often triggered by medications. Antiepileptic drugs, particularly lamotrigine, are recognized as significant causative agents. Early identification and management are crucial to improve patient outcomes. We report the case of a 26-year-old male diagnosed with schizoaffective bipolar disorder who developed SJS following the dose escalation of lamotrigine. He presented with multiple well-defined erythematous lesions, targetoid macular lesions, oral erosions, and fever. Based on clinical findings and a detailed medication history, lamotrigine was identified as the probable causative agent using the World Health Organization (WHO)-Uppsala Monitoring Centre (UMC) causality assessment scale. Laboratory investigations revealed elevated inflammatory markers and Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) assessment predicted a significant mortality risk. Management included immediate discontinuation of lamotrigine, systemic corticosteroids, antihistamines, antibiotics, and topical agents for symptomatic relief. Supportive care led to gradual re-epithelialization, resolution of mucosal lesions, and eventual discharge with residual post-inflammatory hyperpigmentation. This case emphasizes the risk of severe cutaneous adverse reactions with lamotrigine, particularly within the initial weeks of treatment. The pathophysiology of SJS involves immune-mediated keratinocyte apoptosis, with granulysin playing a key role. Current treatment strategies remain debated, with corticosteroids, cyclosporine, and tumor necrosis factor α (TNF-α) inhibitors showing potential benefits. Early drug discontinuation, vigilant monitoring, and multidisciplinary management are crucial in reducing morbidity and mortality. This report underscores the need for heightened vigilance when prescribing lamotrigine, particularly during dose escalation. Strengthening pharmacovigilance, patient education, and screening for genetic predispositions may help mitigate the risk of drug-induced SJS. Further research into optimal therapeutic strategies is warranted to improve clinical outcomes in affected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.